Venous thromboembolism in trauma: an update for the intensive care unit practitioner

Journal of Intensive Care Medicine

Volumn 22, Issue 1, 2007, Pages 26-37

  Rogers, Frederick ^a,c   Rebuck, Jill A ^a   Sing, Ronald F ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Pulmonary embolism; Trauma; Vena cava filter; Venous thromboembolism

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BMS 562247; D DIMER; DABIGATRAN ETEXILATE; DALTEPARIN; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LY 517717; NADROPARIN; NEMATODE ANTICOAGULANT PEPTIDE C2; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

BLEEDING; CHEMOPROPHYLAXIS; CHRONOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPRESSION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; EMERGENCY CARE; EMERGENCY PHYSICIAN; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; INTENSIVE CARE; INTENSIVE CARE UNIT; LIVER TOXICITY; LOW DRUG DOSE; LUNG EDEMA; LUNG EMBOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTIVE CLOTHING; REVIEW; STANDARD; TRAUMATOLOGY; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

HUMANS; INTENSIVE CARE UNITS; MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; THROMBOEMBOLISM; TOMOGRAPHY SCANNERS, X-RAY COMPUTED; VENOUS THROMBOSIS; WOUNDS AND INJURIES;

EID: 33846023002     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606295291     Document Type: Review

References (92)

1. McCartney J. Pulmonary embolism following trauma. Surg Gynecol Obstet. 1935 ; 61: 369-379.
2. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism: a clinicopathologic study in injured and burned patients. Br J Surg. 1961 ; 48: 475-489.
3. Fitts WT Jr, Lehr HB, Bitner RL, Spelman J. An analysis of 950 fatal injuries. Surgery. 1964 ; 56: 663-668.
4. Coon W. Risk factors in pulmonary embolism. Surg Gynecol Obstet. 1976 ; 143: 385-390.
5. Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. J Trauma. 1992 ; 32: 2-11.
6. Shackford SR, Davis JW, Hollingsworth-Fridlind P, Brewer NS, Hoyt DB, Mackersie RC. Venous thromboembolism in patients with major trauma. Am J Surg. 1990 ; 159: 365-369.
7. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994 ; 331: 1601-1606.
8. O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma. 1990 ; 30: 748-750.
9. Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg. 2004 ; 240: 490-496.
10. Lamb GC, Tomski MA, Kaufman J, Maiman DJ. Is chronic spinal cord injury associated with increased risk of venous thromboembolism? J Am Paraplegia Soc. 1993 ; 16: 153-156.
11. Schultz DJ, Brasel KJ, Washington L, et al. Incidence of asymptomatic pulmonary embolism in moderately to severely injured trauma patients. J Trauma. 2004 ; 56: 727-733.
12. Wibbenmeyer LA, Hoballah JJ, Amelon MJ, et al. The prevalence of venous thromboembolism of the lower extremity among thermally injured patients determined by duplex sonography. J Trauma. 2003 ; 55: 1162-1167.
13. Montgomery KD, Potter HG, Helfet DL. The detection and management of proximal deep venous thrombosis in patients with acute acetabular fractures: a follow-up report. J Orthop Trauma. 1997 ; 11: 330-336.
14. Stover MD, Morgan SJ, Bosse MJ, et al. Prospective comparison of contrast-enhanced computed tomography versus magnetic resonance venography in the detection of occult deep pelvic vein thrombosis in patients with pelvic and acetabular fractures. J Orthop Trauma. 2002 ; 16: 613-621.
15. Jensen AD, Borris LC, Christiansen TM, Lundorf E. Accuracy of magnetic resonance imaging in the diagnosis of deep vein thrombosis in asymptomatic patients with injuries of the lower extremity: a pilot study. Thromb Res. 2001 ; 101: 423-426.
16. Owings JT, Gosselin RC, Battistella FD, Anderson JT, Petricj M, Larkin EC. Whole blood D-dimer assay: an effective non-invasive method to rule out pulmonary embolism. J Trauma. 2000 ; 48: 795-799.
17. Johan S, Cemay S, O'Callaghan T, Catalano R. Effect of tissue injury on D-Dimer levels: a prospective study in trauma patients. Med Sci Monit. 2002 ; 8 (1). CR5 - CR8.
18. Wahl WL, Ahrns KS, Zajkowski PJ, et al. Normal D-dimer levels do not exclude thrombotic complications in trauma patients. Surgery. 2003 ; 134: 529-532.
19. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000 ; 132: 227-232.
20. Goodman LR, Lipchik RJ, Kuzo RS, Liu Y, McAuliffe TL, O'Brien DJ. Subsequent pulmonary embolism: risk after a negative helical CT pulmonary angiogram - prospective comparison with scintigraphy. Radiology. 2000 ; 215: 535-542.
21. Wu AS, Pezzullo JA, Cronan JJ, Hou DD, Mayo-Smith WW. CT pulmonary angiography: quantification of pulmonary embolus as a predictor of patient outcome - initial experience. Radiology. 2004 ; 230: 831-835.
22. Virchow R. Gesammele abhandlugen zue wissenschaftlicher medizin, von meidinger sohn. Franfur-ann-Main ; 1856.
23. Seyfer AE, Saeber AV, Dombrose FA, Urbaniak JR. Coagulation changes in elective surgery and trauma. Ann Surg. 1981 ; 193: 210-213.
24. Schmidt U, Enderson BL, Chen JP, Maull KI. D-dimer levels correlate with pathologic thrombosis in trauma patients. J Trauma. 1992 ; 33: 312-319.
25. Attar S, Boyd D, Layne D, McLaughlin J, Mansberger AR, Cowley RA. Alterations in coagulation and fibrinolytic system in acute trauma. J Trauma. 1969 ; 9: 939-965.
26. Mammen EF. Pathogenesis of venous thrombosis. Chest. 1992 ; 102 (6 suppl). 540S - 544S.
27. Knudson MM, Lewis FR, Clinton A, Atkinson K, Meferman J. Prevention of venous thromboembolism in trauma patients. J Trauma. 1994 ; 37: 480-487.
28. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996 ; 335: 701-707.
29. Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P. Prevention of venous thromboembolism after injury: an evidence-based report - part II: analysis of risk factors and evaluation of the role of vena cava filters. J Trauma. 2000 ; 49: 140-144.
30. Jacobs DG, Piotrowski JJ, Hoppensteadt DA, Salvator AE, Fareed J. Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: preliminary results. J Trauma. 1996 ; 40: 710-716.
31. Cornwell EE III, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk patients: a prospective analysis. Am Surg. 2002 ; 68: 470-473.
32. Knudson MM, Morabita D, Paiement GD, et al. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma. 1996 ; 41: 446-459.
33. Greenfield LJ, Proctor MC, Rodriguez JL, et al. Posttrauma thromboembolism prophylaxis. J Trauma. 1997 ; 42: 100-103.
34. Norwood SH, McAuley CE, Berne JD, et al. Use of low molecular weight heparin in preventing venous thromboembolism in high risk blunt trauma patients. J Am Coll Surg. 2001 ; 192: 161-167.
35. Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST Practice Management Guidelines Work Group. J Trauma. 2002 ; 53: 142-164.
36. Rutherford EJ, Schooler WG, Sredzienski E, et al. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma. 2005 ; 58: 1167-1170.
37. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol. 2003 ; 56: 96-103.
38. Sanderik GJ, Guimary CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002 ; 105: 225-231.
39. Mayr AJ, Dünser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002 ; 105: 201-204.
40. Frezza EE, Chiriva-Internati M. Venous thromboembolism in morbid obesity and trauma: a review of literature. Minerva Chir. 2005 ; 60: 391-399.
41. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002 ; 12: 19-24.
42. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg. 2003 ; 90: 547-548.
43. Weitz JI, Hirsch J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (suppl 3). 265S - 286S.
44. Smith W, Moore E, Morgan S, et al. Prevention of venous thromboembolism (VTE) in multisystem trauma patients using a single day dose of low molecular weight heparin. Abstract presented at: 2002 Annual Meeting of the American Association for the Surgery of Trauma ; September 26-28, 2002 ; Orlando, Fla.
45. Chiou-Tan FY, Garza H, Chan KT, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. Am J Phys Med Rehabil. 2003 ; 82: 678-685.
46. The TIFDED Study Group. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin, and dalteparin. Haemostasis. 1999 ; 29: 310-317.
47. Holzeheimer RG. Prophylaxis of thrombosis with low-molecular weight heparin (LMWH). Eur J Med Res. 2004 ; 30: 150-170.
48. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997 ; 8: 114-117.
49. Dager WE, Anderson J, Nutescu E. Special consideration with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy. 2004 ; 24 (7 pt 2). 88S - 94S.
50. Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica. 2004 ; 89: 1017-1018.
51. Turpie AGG, Eriksson BI, Bauer KA, et al. Fondaparinux. J Am Acad Orthop Surg. 2004 ; 12: 371-375.
52. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med. 2002 ; 162: 1833-1840.
53. Eriksson BI, Bauer KA, Lassen MR, et al, for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001 ; 345: 1298-1304.
54. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005 ; 92: 1212-1220.
55. Gulseth MP. Ximelagatran: an orally active direct thrombin inhibitor. Am J Health-Syst Pharm. 2005 ; 62: 1451-1467.
56. Weitz JL, Bates SM. New anticoagulants. J Thromb Haemost. 2005 ; 3: 1843-1853.
57. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005 ; 105: 453-463.
58. PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOeg34006) to replace warfarin for secondary prevention in deep venous thrombosis: a phase II evaluation. J Thromb Haemost. 2004 ; 2: 47-53.
59. Kearon C, Comp P, Douketis JD, et al. A dose-response study of a recombinant human soluble thrombomodulin (ART-123) for prevention in venous thromboembolism after unilateral total hip replacement. J Thromb Haemost. 2003 ; 1 (suppl 1). OC330 - OC330.
60. Murayama N, Tanaka M, Kintada S, et al. Tolerability, pharmacokinetics, and pharmacodynamics of DC-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther. 1996 ; 66: 258-264.
61. Rogers FB, Shackford SR, Wilson J, Ricci MA, Morris CS. Prophylactic vena cava filter insertion in severely injured trauma patients: indications and preliminary results. J Trauma. 1993 ; 35: 637-641.
62. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004: 126: 338S - 400S.
63. Kaufman JA. Retrievable vena cava filters. Tech Vasc Interc Radiol. 2004 ; 7: 96-104.
64. Sing RF, Rogers FB, Novitsky YW, Heniford BT. Optional vena cava filters for patients with high thromboembolic risk: questions to be answered. Surg Innov. 2005 ; 12: 195-202.
65. Fullen WD, Miller EH, Steele WF, McDonough JJ. Prophylactic vena caval interruption in hip fractures. J Trauma. 1973 ; 13: 403-410.
66. Thomas WO III, Ferrara JJ, Rodning CB. A retrospective analysis of inferior vena caval filtration for prevention of pulmonary embolization. Am Surg. 1988 ; 54: 726-730.
67. Rohrer MJ, Scheidler MG, Wheeler HB, Cutler BS. Extended indications for placement of an inferior vena cava filter. J Vasc Surg. 1989 ; 10: 44-49.
68. Webb LX, Rush PT, Fuller SB, Meredith JW. Greenfield filter prophylaxis of pulmonary embolism in patients under-going surgery for acetabular fracture. J Orthop Trauma. 1992 ; 6: 139-145.
69. Wilson JT, Rogers FB, Wald SL, Shackford SR, Ricci MA. Prophylactic vena cava filter insertion in patients with traumatic spinal cord injury: preliminary results. Neurosurgery. 1994 ; 35: 234-239.
70. Zolfaghari D, Johnson B, Weireter LJ, Britt LD. Expanded use of inferior vena cava filters in the trauma population. Surg Annu. 1995 ; 27: 99-105.
71. Patton JH Jr, Fabian TC, Croce MA, Minard G, Pritchard FE, Kudsk KA. Prophylactic Greenfield filters: acute complications and long-term follow-up. J Trauma. 1996 ; 41: 231-236.
72. Nunn CR, Neuzil D, Naslund T, et al. Cost-effective method for bedside insertion of vena caval filters in trauma patients. J Trauma. 1997 ; 43: 752-758.
73. Rogers FB, Strindberg G, Shackford SR, et al. Five-year follow-up of prophylactic vena cava filters in high-risk trauma patients. Arch Surg. 1998 ; 133: 406-411.
74. Langan EM III, Miller RS, Casey WJ III, Carsten CG III, Graham RM, Taylor SM. Prophylactic inferior vena cava filters in trauma patients at high risk: follow-up examination and risk/benefit assessment. J Vasc Surg. 1999 ; 30: 484-488.
75. Hughes GC, Smith TP, Eachempati SR, Vaslef SN, Reed RL II. The use of a temporary vena caval interruption device in high-risk trauma patients unable to receive standard venous thromboembolism prophylaxis. J Trauma. 1999 ; 46: 246-249.
76. Wojcik R, Cipolle MD, Fearen I, Jaffe J, Newcomb J, Pasquale MD. Long-term follow-up of trauma patients with a vena caval filter. J Trauma. 2000 ; 49: 839-843.
77. Sekharan J, Dennis JW, Miranda FE, et al. Long-term follow-up of prophylactic Greenfield filters in multisystem trauma patients. J Trauma. 2001 ; 51: 1087-1090.
78. Rosenthal D, Wellons ED, Levitt AB, Shuler FW, O'Conner RE, Henderson VJ. Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. J Vasc Surg. 2004 ; 40: 958-964.
79. Morris CS, Rogers FB, Najarian KE, Bhave AD, Shackford SR. Current trends in vena caval filtration with the introduction of a retrievable filter at a level I trauma center. J Trauma. 2004 ; 57: 32-36.
80. Leach TA, Pastena JA, Swan KG, Tikellis JI, Blackwood JM, Odom JW. Surgical prophylaxis for pulmonary embolism. Am Surg. 1994 ; 60: 292-295.
81. Rosenthal D, McKinsey JF, Levy AM, Lamis PA, Clark MD. Use of the Greenfield filter in patients with major trauma. Cardiovasc Surg. 1994 ; 2: 52-55.
82. Winchell RJ, Hoyt DB, Walsh JC, Simons RK, Eastman AB. Risk factors associated with pulmonary embolism despite routine prophylaxis: implications for improved protection. J Trauma. 1994 ; 37: 600-606.
83. Khansarinia S, Dennis JW, Veldenz HC, Butcher JL, Hartland L. Prophylactic Greenfield filter placement in selected high-risk trauma patients. J Vasc Surg. 1995 ; 22: 231-235.
84. Rogers FB, Shackford SR, Ricci MA, Wilson JT, Parsons S. Routine prophylactic vena cava filter insertion in severely injured trauma patients decreases the incidence of pulmonary embolism. J Am Coll Surg. 1995 ; 180: 641-647.
85. Rodriguez JL, Lopez JM, Proctor MC, et al. Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism. J Trauma. 1996 ; 40: 797-802.
86. Gosin JS, Graham AM, Ciocca RG, Hammond JS. Efficacy of prophylactic vena cava filters in high-risk trauma patients. Ann Vasc Surg. 1997 ; 11: 100-105.
87. Headrick JR Jr, Baker DE, Pate LM, Horne K, Russell WL, Burns RP. The role of ultrasonography and inferior vena cava filter placement in high-risk trauma patients. Am Surg. 1997 ; 63: 1-8.
88. Rogers FB, Shackford SR, Ricci MA, Huber BM, Atkins T. Prophylactic vena cava filter insertion in selected high-risk orthopaedic trauma patients. J Orthop Trauma. 1997 ; 11: 267-272.
89. Sing RF, Camp SM, Heniford BT, et al. Timing of pulmonary emboli after trauma: implications for retrievable vena cava filters. J Trauma. 2006 ; 60: 732-734.
90. National Trauma Data Bank. NTDB online. Available at: http://web.facs.org/ntdb_cf/demon_.cfm?. Accessed November 28, 2005.
91. Quirke TE, Ritota PC, Swan KG. Inferior vena cava filter use in U.S. trauma centers: a practitioner survey. J Trauma. 1997 ; 43: 333-337.
92. Brasel KJ, Borgstrom DC, Weigelt JA. Cost-effective prevention of pulmonary embolism in high risk patients. J Trauma. 1997 ; 42: 456-460.